Epoprostenol vs Treprostinil (Yutrepia, Liquidia)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Pulmonary Arterial Hypertension

Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline

Epoprostenol · Flolan

Rights held by GlaxoSmithKline; US product discontinued

Approved in Pulmonary Arterial Hypertensionsmall molecule (prostacyclin)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Treprostinil (Yutrepia, Liquidia)

Marketed by Liquidia Corporation

Approved in Pulmonary Arterial Hypertensionsmall molecule (prostacyclin analogue, inhaled dry powder)
Weak signal

NCT03399604 · Phase 3 · completed

The study was an open-label, single-group trial with 121 participants and no placebo or active comparator. Its primary endpoint was treatment-emergent and serious adverse events, rather than a controlled clinical efficacy outcome, so the findings provide limited evidence about the treatment’s comparative effectiveness.

Next expected readout: May 2027 · NCT07759804 (registry estimate)

Reported efficacy

Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events (Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 16 months.): Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events (Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 16 months.): LIQ861 Inhaled Treprostinil 121 Participants (not_applicable)

Result source: NCT03399604

Results for Pulmonary Arterial Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

Coverage. Epoprostenol: 3 of 4 rows · Treprostinil (Yutrepia, Liquidia): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEpoprostenolTreprostinil (Yutrepia, Liquidia)
Dropout rate
0%a
NCT01462565 · Phase 4 · registry result, not featured evidence
show 2 more results
0%
NCT01105117 · Phase 4 · registry result, not featured evidence
10%
NCT01105091 · Phase 4 · registry result, not featured evidence
—LIQ861 Add-On
NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3
show 1 more result
24%LIQ861 Inhaled Treprostinil
NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3
Discontinued due to AEs
—a
NCT01462565 · Phase 4 · registry result, not featured evidence
show 2 more results
—
NCT01105117 · Phase 4 · registry result, not featured evidence
—
NCT01105091 · Phase 4 · registry result, not featured evidence
—LIQ861 Add-On
NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3
show 1 more result
—LIQ861 Inhaled Treprostinil
NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3
Serious AEs
12.5%a
NCT01462565 · Phase 4 · registry result, not featured evidence
show 2 more results
0%
NCT01105117 · Phase 4 · registry result, not featured evidence
30%
NCT01105091 · Phase 4 · registry result, not featured evidence
12.4%LIQ861 Add-On
NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3
show 1 more result
—LIQ861 Inhaled Treprostinil
NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3
Most frequent reported AEs
a
diarrhoea 12.5%
fatigue 12.5%
headache 12.5%
NCT01462565 · Phase 4 · registry result, not featured evidence
show 2 more results
catheter site erythema 100%
flushing 0%
NCT01105117 · Phase 4 · registry result, not featured evidence
pain in jaw 75%
headache 65%
nausea 50%
NCT01105091 · Phase 4 · registry result, not featured evidence
cough 33.9%
headache 19%
upper respiratory tract infection 14.9%
NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Epoprostenol

SF-36 Physical Functioning -1.156 score @ 4wk
absolute change · score
No placebo or comparator arm
Physical Functioning
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 - Role Physical -0.765 score @ 4wk
absolute change · score
No placebo or comparator arm
Role-Physical
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 - Role Emotional 0.002 score @ 4wk
absolute change · score
No placebo or comparator arm
Role-Emotional
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 Vitality 0.781 score @ 4wk
absolute change · score
No placebo or comparator arm
Vitality
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 Social Functioning 1.706 score @ 4wk
absolute change · score
No placebo or comparator arm
Social Functioning
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 Bodily Pain 3.065 score @ 4wk
absolute change · score
No placebo or comparator arm
Bodily Pain
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 General Health -0.606 score @ 4wk
absolute change · score
No placebo or comparator arm
General Health
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 Physical Component Summary -0.123 score @ 4wk
absolute change · score
No placebo or comparator arm
Physical Health Component
NCT01462565 · Phase 4 · registry result, not featured evidence
6MWD - Change -3.55 m @ 4wk
absolute change · m
No placebo or comparator arm
NCT01462565 · Phase 4 · registry result, not featured evidence
Borg Dyspnea 0.36 score @ 4wk
absolute change · score
No placebo or comparator arm
NCT01462565 · Phase 4 · registry result, not featured evidence
6MWD - Change 288 vs 323.5 Epoprostenol Sodium for Injection m @ 4wk
absolute change · m
NCT01105091 · Phase 4 · registry result, not featured evidence
SvO2 58% (n=11) vs 56% (n=6) Epoprostenol Sodium for Injection @ 4wk
absolute change · percentage points
NCT01105091 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Epoprostenol's landscape · Treprostinil (Yutrepia, Liquidia)'s landscape